MedTrace Logo

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

NCT05093998 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2021-10-26

No results posted yet for this study

Summary

To evaluate the efficacy of AV5080 versus Placebo based on time to symptom resolution in patients with uncomplicated influenza.

Conditions

Interventions

DRUG

AV5080

oral hard gelatin capsules

OTHER

Placebo

Hard gelatin capsules with a white body

Sponsors & Collaborators

  • Viriom

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2023-07-15
Completion
2023-07-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05093998 on ClinicalTrials.gov